Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting Vδ2+ T cells activities after hematopoietic transplantation for blood malignancies
BackgroundFollowing the extensive use of immunosuppressive drugs in the clinic, immunosuppression-associated side effects have received increasing attention. Epstein-Barr virus (EBV) reactivation and related lymphoproliferative diseases (LPD) are the lethal complications observed after allogeneic he...
Main Authors: | Jiangying Liu, Haitao Gao, Lan-Ping Xu, Xiao-Dong Mo, Ruoyang Liu, Zhidong Wang, Ying-Jun Chang, Xiao-Hui Zhang, Xiao-Jun Huang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-06-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/8/1/e000208.full |
Similar Items
-
Dendritic Cells Are Critical for the Activation and Expansion of Vδ2+ T Cells After Allogeneic Hematopoietic Transplantation
by: Xiaoyu Wang, et al.
Published: (2018-11-01) -
EBV-Associated Lymphoproliferative Disorders
by: Young Hyeh Ko
Published: (2021-04-01) -
Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice.
by: Nicole Caduff, et al.
Published: (2020-04-01) -
Correction: Immunosuppressive FK506 treatment leads to more frequent EBV-associated lymphoproliferative disease in humanized mice.
by: Nicole Caduff, et al.
Published: (2020-12-01) -
Quantifying EBV-specific CD8⁺ T cell immunity in patients with post transplant lymphoproliferative disease (PTLD) and other EBV-driven malignancies
by: Guppy, Amy Elizabeth
Published: (2008)